-transparent.png){kind=logo}
In a double-blind, randomised, cross-over trial clofibrate and a combination of polyenyl phosphatidyl choline (PPC) plus clofibrate were tested in 67 patients with hyperlipoproteinemia. Each treatment lasted for 4 weeks and was separated by a 4 week placebo period. The daily doses were clofibrate 1.2 g and PPC 1.8 g + clofibrate 1.2 g. respectively. The results revealed that polypenyl phosphatidyl choline prevented the elevation of LDL-cholesterol induced by clofibrate treatment, and that the lipid-lowering potency of the combination did not differ significantly from that of clofibrate. Since elevation of LDL-cholesterol is considered to increase the risk of coronary heart disease, the combination appears to offer a therapeutic advantage. Despite the significance of this clinical observation, a final decision may only be obtained from a prospective, long term investigation in patients with coronary heart diseases and hyperlipoproteinemia.
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
January 1955,
Circulation research,
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
September 2009,
Journal of psychopharmacology (Oxford, England),
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
October 1972,
British journal of experimental pathology,
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
November 1986,
Experimental cell research,
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
August 2007,
Psychopharmacology,
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
November 1970,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
January 1974,
Atherosclerosis,
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
June 1972,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
September 1977,
Archives of biochemistry and biophysics,
J Schneider, and
R Müller, and
W Buberl, and
H Kaffarnik, and
R Schubotz, and
L Hausmann, and
G Mühlfellner, and
O Mühlfellner
January 1972,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
